Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis
Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis
复制标题
DOI：
10.1016/j.canlet.2005.06.040
复制
发表时间：
2005-11-18
期刊：
影响因子：
9.7
通讯作者：
Miyauchi, A
中科院分区：
文献类型：
--
作者：
Ito, Y;Yoshida, H;Miyauchi, A
cdc25B和cdc25A磷酸酶是细胞周期进程的突出刺激物，并已被认为发挥致癌作用。在这项研究中，我们采用化学方法研究了这些磷酸酶在甲状腺髓样癌中的表达。Cdc25B阳性率为35.8%。它的积极性仅与患者年龄有关。然而，cdc25B阳性肿瘤患者的无病生存率（P=0.0210）显著低于cdc25B阴性肿瘤患者。Cdc25A仅在17.2%的病例中呈阳性，与临床病理参数或预后无关。这些结果表明，cdc25 B可以被视为具有预后意义，并作为一种新的标志物的生物学侵略性的特点，在这种癌。(c)2005爱思唯尔爱尔兰有限公司保留所有权利。
Cdc25B and cdc25A phosphatases are prominent stimulators of cell cycle progression and have been suggested to play oncogenic roles. In this study, we immunohistochemically investigated the expression of these phosphatases in medullary thyroid carcinoma. Cdc25B was positive in 35.8% of cases examined. Its positivity was linked only to patient age. However, patients with cdc25B-positive tumors showed a significantly worse disease-free survival rate (P=0.0210) than those with cdc25B-negative tumors. Cdc25A was positive in only 17.2% of cases and was not related to clinicopathological parameters or prognosis. These findings suggest that cdc25B can be regarded as having prognostic significance and as a novel marker of biologically aggressive characteristics in this carcinoma. (c) 2005 Elsevier Ireland Ltd. All rights reserved.